When used prophylactically in respiratory infections due to influenza virus or rhinoviruses, intranasal exogenous human leukocyte-derived interferon decreased the symptoms and frequency of virus shedding and led to a decreased antibody production (25, 28) . Likewise, interferon administered parenterally suppressed hepatitis B virus and Dane particle markers, inhibited viruria transiently in cytomegalovirus infections, and shortened the duration of pain while facilitating crust formation in adults with herpes zoster (2, 11, 12, 15, 24) . Human interferon has also been given prophylactically to patients with malignancies to attempt to protect against acute infections (1, 30) .
The difficulty of extensive controlled clinical testing with exogenous interferon in humans is great because to treat one patient many 500-ml units of whole blood must be processed (18) . Therefore, endogenous induction of interferon has been explored. Polyinosinic-polycytidylic acid [poly(I:C)] is an effective antiviral agent in rodents (4, 18, 32) . Unfortunately, poly(I:C) is rapidly hydrolyzed by nucleolytic enzymes in primate sera, resulting in poor interferon induction (17, 26) . Recently, one of us (H.B.L.) prepared a soluble complex of poly(I:C) with poly-L-lysine and carboxymethyl cellulose [poly(I:C. LC)] which is 5 to 10 times more resistant to primate serum than the parent poly(I:C) and induces significant levels of serum interferon in monkeys and chimpanzees under conditions in which poly(I:C) itself induces no interferon (23) . Poly(I:C-LC) has been shown to be effective in the prophylaxis of simian hemorrhagic fever, rabies, yellow fever, and hepatitis in nonhuman primates (22) . No toxic effects due to poly(I:C. LC) were observed. The purpose of this initial phase 1 clinical trial was to determine dose responses and the possible toxic effects ofpoly(I:C -LC) in humans with virus infections (33) .
MATERIALS AND METHODS Administration of poly(I:C.LC). Poly(I:C LC) was prepared and stored (40C) as before (23 (21) . After collection, sera were stored (40C), frozen (-200C) within 24 h, and thawed once at assay. In earlier studies in primates, it has been shown that when poly(I:C. LC) is given intravenously it is removed from the circulation, probably by the mononuclear phagocytic system, within 10 min. Isolated human sera here were tested for residual poly(I:C. LC) in nonhuman tissue cultures. No residual poly(I: C * LC) remained in serum. Interferon levels in sera of patients were measured in human foreskin fibroblast tissue cultures, using vesicular stomatitis virus as challenge virus as previously described (23, 27) . Titers were expressed as reference units after adjustment to the human reference interferon standard (National Institute of Allergy and Infections Diseases catalog no. G023901537).
RESULTS
Interferon in serum. When testing for interferon in serum, in each case, blood was taken before beginning treatment with poly(I:C LC) ( Fig. 1 ). These specimens contained no detectable interferon. Similar specimens were taken from patients with SLE who were treated supportively. Only 1 of 18 of these sera had a detectable interferon titer (32 U/ml). On the other hand, poly(I:C LC) induced significant levels of serum interferon. The only exception was a 62-year-old man with bronchogenic carcinoma and disseminated varicella-zoster infection who had no interferon response, despite five or six daily doses of 0.20 mg of poly(I:C * LC) per kg. Otherwise, on day 1 of the poly(I:C.LC) infusions, interferon titers ranged from <50 to 800 U/ml, with higher doses of the inducer generally producing the greater and more prolonged response. Peaks occurred 8 to 16 h after infusions. Mean peak levels were 70, 250, and 675 U/ml in patients receiving 0.1, 0.2, and 0.3 mg of poly(I:C. LC) per kg, respectively. After the first and second infusions, these interferon levels persisted for 12 to 48 h, but beginning with day 3 of the 5-day schedules, lower levels were found.
In striking contrast to this usual response, a Two patients died during the course of this study: a 14-year-old girl with Hodgkin's disease and disseminated varicella-zoster with myocarditis and pneumonia. (At autopsy, varicella-zoster virus was isolated from the heart and lung in human foreskin fibroblast tissue cultures.) This illness was terminal at the time poly(I:C.LC) was initially given, and the cardiovascular collapse and death of the patient cannot be attributed to poly(I:C-LC). The 69-year-old woman with multiple myeloma, renal insufficiency, and disseminated varicella-zoster was also very seriously ill at the time poly(I:C.LC) was given. Whether poly(I:C * LC) contributed to her illness cannot be stated, but it may be that poly(I:C. LC) should be administered with special caution to patients with compromise of their mononuclear phagocytic function (e.g., liver and spleen), lymphoma, multiple myeloma, and renal insufficiency. This possibility will have to be considered in further studies.
Laboratory findings (lymphopenia, increased hepatic enzymes). Transient absolute lymphopenias (<1,000 cells per mm3) developed after the first infusion of poly(I:C.LC) in 10 of the 14 patients. Lymphopenia persisted for 2 to 5 days before returning to normal (Fig. 3) . These peripheral lymphopenias could well have been due, at least in part, to concurrent viral diseases. We did not determine whether lymphopenias were deficiencies of thymus-or marrow-derived cells, or both. Transient leukocytoses (>10,000 cells per mm:), along with "shifts to the left" >5% juveniles), followed in several patients. No other hematological alterations were noted.
Elevations of hepatic enzymes are diagnostic in virus hepatitis and are usual, but of lesser severity, in patients with SLE (29) . Therefore, rises in serum glutamic oxalacetic transaminase and lactic dehydrogenase were attributed to poly(I:C * LC) only in patients with no other ob- vious cause of hepatic derangement. The latter are seen in Fig. 4 . Elevations of hepatic enzymes were dose related, mild to moderate in severity (_200 U/ml), increased with repeated infusions, and returned to normal within several days after poly(I:C -L) was stopped. Alkaline phosphatase, serum bilirubin, renal function, and clotting test results remained normal. At autopsy, the patient who died of multiple myeloma had no hepatic abnormalities.
Neurological scores in patients with SLE. In poly(I:C.LC) and symptomatically treated (Fig. 5) . Patients receiving poly(I: C-LO) were sicker (higher neurological score) and older [mean age of the poly(I:C * LC)-treated group, 63.4 years; mean age of "control," 52. 6 years]. Likewise, the average duration of symptoms before admission was 4.5 days in the poly(I: C* LC) group, but control patients were admitted to the hospital on day 1 of illness. Neither a beneficial nor deleterious effect for poly(I:C.
LO) was evident and, of course, this phase 1 study was not designed to assess clinical efficacy. DISCUSSION Poly(I:C-LC) induces high titers of interferon when given intravenously to monkeys, chimpanzees (23) , and as shown here, to humans. Inter- Toxic effects of poly(I:C-LC) were fever, hypotension, lymphopenia, and increases in serum glutamic oxalacetic transaminase and lactic dehydrogenase. These toxic effects lessened as did in humans were somewhat lower interferon titers on days 3 to 5 of the adminis-,een in some primates, but higher tration of poly(I:C-LC). Such amelioration of y(I:C-LC) were used in the latter the effects of interferon inducers has been deese studies of patients with virus fined as a "hyporeactive state." After poly(I:CLe intravenous doses of 0.2 to 0.3 mg LC) was stopped, all abnormalities disappeared.
LG) per kg were most active. The Hypotension, fever, lymphopenia, interferorferon we observed are significantly nemia, and tolerance (hyporeactivity) of poly(I: those obtained with unmodified C-LC) are reminiscent of endotoxemia in raband compare favorably with levels bits. Tolerance to bacterial endotoxin has been found in sera of patients treated ascribed to a facilitated capacity of the monomillion units per day of exogenous nuclear phagocytic system to clear this macro-5). It would be most useful if further molecule from the blood (3, 34) . Facilitated lessen the effects on interferon in-clearance of poly(I:C . LC) is an alternate explahe hyporeactive period, but never-nation for the induction of the hyporeactive e findings are encouraging. Caution state. It is unclear which of the toxic effects may ecause of the hypotensive episodes be due to poly(I:C -LC) or, in turn, the induced our patients experienced. However, interferon. Indeed, exogenous interferon in huudies at the National Cancer Insti-mans has caused fever, leukopenia, hypotension, mine and one of us (H.B.L.) have and falls in platelet and reticulocyte counts (5, Is hypotensive responses less fre-10, 15, 19, 31) .
reported here (A. Levine, and H. Finally, no evident benefit resulted from the rsonal communication). It may be use of poly(I:C * LC) in these patients. However, with malignancies other than mul-it is important to note that serum interferon .a may be less responsive to the side diffuses very poorly into the cerebrospinal fluid ve noted. and brain (5, 7, 10, 16) . Although the hypotensive ort, stimulated leukocyte cultures effects of the present preparation of poly(I:C. s with solid tumors produce 2 to 16 LC) are a cause for concern, they may be ameterferon than similar cells from nor-nable to pharmacological management. A comi one patient here with carcinoma panion paper in which poly(I:C-LC) is infused had no rise in interferon titer or intravenously in rabbits addresses this possibility (B. 
